Skip to main content
. 2018 Feb 9;9(17):13733–13747. doi: 10.18632/oncotarget.24460

Figure 4. IHC analysis of the RG derived tumors.

Figure 4

(A1, A2) Trim22 5x, 63x (LCAS-R 12 weeks post-injection) - intense expression is observed in all tumor cells, (A3, A4) ENO1 10x, 63x (LCAS-R 12 weeks post-injection) - intense expression is observed in all tumor cells, within the main tumor mass and in perivascular invading areas, (B1, B2) MALT1 5x, 63x (LC25-R 8 weeks post-injection, LCAS-R 12 weeks post-injection) - intense expression in over 75% of tumor cells within the main tumor mass and in 100% of the perivascular invading cells, (B3) Caveolin 1 40x (LCAS-R 12 weeks post-injection) - extensively expressed in tumor cells, (B4) Cathepsin C 20x (LC26-R 12 weeks post-injection)- extensively expressed in tumor cells. TU-tumor; P-parenchyma; V-ventricle; PI- perivascular invasion.